# Table of Contents

## Highlights of This Issue

### REVIEW

2185  Cabozantinib in Combination with Immunotherapy for Advanced Renal Cell Carcinoma and Urothelial Carcinoma: Rationale and Clinical Evidence  
Paulo Bergerot, Peter Lamb, Evelyn Wang, and Sumanta K. Pal

## SMALL MOLECULE THERAPEUTICS

2194  FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGFR19-Driven Hepatocellular Cancer  
Andreas Weiss, Flavia Adler, Alexandra Buhles, Christelle Stamn, Robin A. Fairhurst, Michael Kiff, Dario Sterker, Mario Centeleghe, Markus Wattmann, Jacqueline Kinyamu-Akunda, Heiko S. Schadt, Philippe Couttet, Armin Wolf, Yuzhen Wang, Patrizia Barzaghi-Rinaudo, Masato Muzakami, Audrey Kauffmann, Thomas Knoepfel, Nicole Buschmann, Catherine Leblanc, Robert Mah, Pascal Furet, Jutta Blank, Francesco Hofmann, William B. Kietzman, Virginie Ory, Ghada M. Sharif, Anton Wellstein, and Anna T. Riegel

## Ovarian Primary and Metastatic Tumors Suppressed by Survivin Knockout or a Novel Survivin Inhibitor

2233  Ovarian Primary and Metastatic Tumors Suppressed by Survivin Knockout or a Novel Survivin Inhibitor  
Guannan Zhao, Qinghui Wang, Zhonghi Wu, Xinchen Tian, Huan Yan, Baijin Wang, Peixin Dong, Hidemichi Watari, Lawrence M. Pfeffer, Yuqi Guo, Wei Li, and Junming Yue

## Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T cell Function against Multiple Myeloma Is Enhanced in the Presence of Lenalidomide

2246  Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T cell Function against Multiple Myeloma Is Enhanced in the Presence of Lenalidomide  
Melissa Works, Neha Soni, Collin Hauskins, Catherine Sierra, Alex Baturevych, Ion C. Jones, Wendy Curtis, Patrick Carlson, Timothy G. Johnstone, David Kugler, Ronald J. Hause, Yue Jiang, Lindsey Wimberly, Christopher R. Clouser, Heidi K. Jessup, Rhythe Sather, Ruth A. Salmon, and Michael O. Potts

## Lenalidomide Augments the Antitumor Activities of Eps8 Peptide-Specific Cytotoxic T Lymphocytes against Multiple Myeloma

2258  Lenalidomide Augments the Antitumor Activities of Eps8 Peptide-Specific Cytotoxic T Lymphocytes against Multiple Myeloma  
Xiaoling Xie, Yiran Chen, Yu-Xing Hu, Yanjie He, Honghao Zhang, and Yuhua Li

## Fenretinide via NOXA Induction, Enhanced Activity of the BCL-2 Inhibitor Venetoclax in High BCL-2–Expressing Neuroblastoma Preclinical Models

2270  Fenretinide via NOXA Induction, Enhanced Activity of the BCL-2 Inhibitor Venetoclax in High BCL-2–Expressing Neuroblastoma Preclinical Models  
Thinh H. Nguyen, Balakrishna Koneru, Sung-Jen Wei, Wan Hsi Chen, Monish Ram Makena, Eduardo Urias, Min H. Kang, and C. Patrick Reynolds

## CNDAC-Induced DNA Double-Strand Breaks Cause Aberrant Mitosis Prior to Cell Death

2283  CNDAC-Induced DNA Double-Strand Breaks Cause Aberrant Mitosis Prior to Cell Death  
Xiaojun Liu, Yingjun Jiang, Kei-ichi Takata, Billie Nowak, Chaomei Liu, Richard D. Wood, Walter N. Hittelman, and William Plunkett

## Fenretinide, Tocilizumab, and Reparixin Provide Multifaceted Disruption of Oral Squamous Cell Carcinoma Stem Cell Properties: Implications for Tertiary Chemoprevention

2308  Fenretinide, Tocilizumab, and Reparixin Provide Multifaceted Disruption of Oral Squamous Cell Carcinoma Stem Cell Properties: Implications for Tertiary Chemoprevention  
Susan R. Mallery, Daren Wang, Brian Santiago, Ping Pei, Caroline Bissonnette, Jiyawardena, Steven P. Schwendeman, Richard Skipney, and James Lang

---

Downloaded from mct.aacrjournals.org on June 11, 2021. © 2019 American Association for Cancer Research.
LncRNA CCAT1 Promotes Prostate Cancer Cell Proliferation by Interacting with DDX5 and MIR-28-5P
Zonghao You, Chunhui Liu, Can Wang, Zhixin Ling, Yiduo Wang, Yali Wang, Minghao Zhang, Shuqiu Chen, Bin Xu, Han Guan, and Ming Chen

Expression Levels of Therapeutic Targets as Indicators of Sensitivity to Targeted Therapeutics
Riti Roy, Louise N. Winteringham, Timo Lassmann, and Alistair R.R. Forrest

ABOUT THE COVER
Pancreatic cancer is notoriously difficult to treat. One potential opportunity for targeting pancreatic cancer is through its modified amino acid metabolism. Specifically, depriving arginine-dependent tumor cells of arginine can lead to cell death. To achieve this, a polyethylene glycol (PEG)-conjugated arginine deiminase construct (ADI-PEG20) was previously designed and tested as a monotherapy in clinical studies with limited success. In the cover image, adapted from Figure 3 of the associated manuscript, Singh and colleagues demonstrate ADI-PEG20 radiosensitized pancreatic cancer cells by inducing ER stress (red fluorescence, BIP). Therefore, ADI-PEG20 could be combined with radiation therapy in patients whose tumors are arginine-dependent. Read the full study on page 2381.